Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text

Crystal Structure, Molecular Biology, Cell Growth +20

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

Fortunato Ciardiello, Giampaolo Tortora · PubMed · 2001 · 988 citations

Immunology, Novel Approach, Egfr Inhibitors +18

BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

PubMed · 2025 · 933 citations · Full text

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Andrew Barker, Keith H. Gibson, Walter Grundy et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 559 citations · Full text

Molecular Pharmacology, Drug Targeting, Oncology +10

Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor

Alexander J. Bridges, Hairong Zhou, Donna R. Cody et al. · Journal of Medicinal Chemistry · 1996 · 321 citations · Full text